Purchase this article with an account.
L. Thompson, M. Adenwalla, J.C. Whelchel, A. Elbiaadi, P.B. Dray, R.M. Ahuja; The Use of Subconjunctival Mitomycin C Preoperatively for Management of Pterygium . Invest. Ophthalmol. Vis. Sci. 2004;45(13):2937.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose:To evaluate the efficacy and safety of using of 0.10 ml of 0.10 mg/ml mitomycin C as adjunctive therapy before pterygium surgery. Methods: A retrospective review of 30 eyes of 22 consecutive patients with no prior history of pterygium surgery treated with subconjunctival injection of 0.10 ml of 0.10 mg/ml mitomycin C one month prior to bare sclera pterygium excision. Our main outcome measures were recurrence of pterygium and patient satisfaction. Results:The pterygia resolved in 96% (29) of patients with an average follow up time of 2.2 months (range of 1.3 to 3.2 months). All but one patient expressed satisfaction with the postoperative results. Four (12%) patients suffered from transient post–injection blepharoconjunctivitis, and one patient complained of transient diplopia on extreme lateral gaze following excision at 2 months follow–up. Conclusions: Based on previous studies using higher doses of mitomycin C with successful outcomes, we conducted this study to determine whether a lower dose could prove equally effective but with lower adverse effects such as post–injection blepharoconjunctivitis in addition to other side effects. Based on a limited mean follow up time of 2.2 months, the lower dose of preoperatively injected subconjunctival mitomycin C is thus far effective in the treatment of pterygium with regards to recurrence and patient satisfaction. However, the adverse effect of blepharoconjunctivitis remains similar to prior studies.
This PDF is available to Subscribers Only